The Latest Cardiac and Vascular News
Cary, N.C. and Basel, Switzerland, May 06, 2021 (GLOBE NEWSWIRE) — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company has initiated its ELEVATE 2 Study, a Phase 2b clinical trial of its lead product candidate, rodatristat ethyl (“rodatristat”), for the […]
WEST CONSHOHOCKEN, Pa., May 06, 2021 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights. “We expect several important events for Madrigal to occur in 2021,” stated Paul Friedman, M.D., Chief Executive Officer of Madrigal. “These include completing enrolling a sufficient number […]
SANTA MONICA, Calif.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (NASDAQ: OTRKP) (“Ontrak” or the “Company”) today announced that its Board of Directors has declared the third quarterly cash dividend for the Company’s 9.50% Series A Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock”). The third quarterly cash dividend equals $0.593750 per share, at […]
New RapidAI Insights Improves Hospitals’ Understanding of Their Stroke Businesses, as Well as Patient Workflow and Outcomes MENLO PARK, Calif.–(BUSINESS WIRE)–RapidAI, the leader in advanced cerebrovascular imaging, today announced the expansion of RapidAI Insights, a unique analytics solution that uses Rapid® scan, treatment, and outcome data to enable hospitals and […]
SUNNYVALE, Calif., May 04, 2021 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the quarter ended March 31, 2021. “Our first quarter results were characterized by meaningful progress on several commercial […]
Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETON study of Tyvaso in idiopathic pulmonary fibrosis (IPF) expected to enroll its first patients in the second quarter of 2021 SILVER SPRING, […]
On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 5, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights. “In the first quarter, we took important steps to maximize […]
ANDOVER, Mass., May 4, 2021 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2021. Recent Highlights Net revenue of $7.1 million in the first quarter of 2021, […]
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets – – Secured Major Medicare Part D Contract Covering Approximately 8.5 Million Lives – – […]
CALGARY, Alberta, May 05, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”) which provides for Hepalink to purchase 10% secured convertible debentures of the Company […]
